An eagerly awaited Phase I/II study of Roche’s Zelboraf and Bristol-Myers Squibb Co.’s Yervoy has been terminated due to liver toxicity, but the drugs still could find a role for use in immediate sequence.
Both Bristol’s CTLA inhibitor Yervoy (ipilimumab) and Roche’s BRAF inhibitor Zelboraf (vemurafenib) revolutionized the melanoma field when they cleared FDA...